This page explores the mechanistic basis for amino acid supplementation in Parkinson's disease (PD), with focus on clinical trial NCT06954662: "A Targeted Amino Acid Supplement for People With Parkinson's Disease." The trial investigates whether specialized amino acid formulations can improve dopaminergic medication efficacy by optimizing large neutral amino acid transporter (LAT1) function at the blood-brain barrier.
| Parameter | Value |
|---|---|
| NCT Number | NCT06954662 |
| Status | Recruiting |
| Phase | Not Applicable |
| Sponsor | Oncovistan Clinical Corp |
| Intervention | Amino acid supplement vs. whey protein vs. placebo |
| Primary Outcome | Levodopa bioavailability and motor function |
| Enrollment | Not specified |
| Study Design | Randomized, controlled trial |
Levodopa, the gold-standard treatment for Parkinson's disease, faces a fundamental pharmacological challenge: its journey from the gastrointestinal tract to the brain is compromised by competition with dietary amino acids.[1]
When patients take levodopa with high-protein meals, the medication must compete with naturally occurring amino acids for absorption and brain entry. This competition occurs at two critical interfaces:
The protein-levodopa interaction has measurable clinical consequences:
LAT1 (SLC7A5) is a heteromeric amino acid transporter that mediates the transport of large neutral amino acids across the blood-brain barrier. It operates as part of the system L transporter family, which handles:
LAT1 is a heterodimeric transporter composed of:
The transporter functions as a sodium-independent exchanger, using the concentration gradient of intracellular amino acids to drive uptake of extracellular substrates. At the blood-brain barrier, LAT1 is expressed on the luminal (blood-facing) and abluminal (brain-facing) membranes, facilitating bidirectional amino acid transport.[5]
LAT1 function is altered in several neurological conditions:
| Condition | LAT1 Alteration | Implications |
|---|---|---|
| Parkinson's Disease | Competition with levodopa | Reduced medication efficacy |
| Alzheimer's Disease | Downregulation reported | Impaired amino acid delivery |
| Brain Tumors | Overexpression | Nutrient supply for tumors |
| Epilepsy | Dysregulation | Altered neurotransmitter precursors |
Several studies have identified changes in amino acid metabolism in Parkinson's disease patients:[6]
Amino acids serve as precursors for neurotransmitters affected in Parkinson's disease:
When levodopa and dietary amino acids are present simultaneously in the bloodstream, they compete for LAT1-mediated transport into the brain. The kinetics of this competition follow basic principles:
Several approaches have been investigated to improve levodopa delivery despite transport competition:
Clinical trial NCT06954662 evaluates a targeted amino acid supplement designed to optimize LAT1 function. The hypothesis is that:
The amino acid supplement in NCT06954662 is hypothesized to work through several mechanisms:
Beyond transport, amino acid supplementation may influence:
Research on amino acid-levodopa interactions spans decades:
| Study | Finding |
|---|---|
| Nutt et al., 1984 | High-protein meals reduce levodopa bioavailability |
| Simon et al., 2010 | Protein redistribution improves motor fluctuations |
| Cereda et al., 2013 | Altered amino acid profiles in PD patients |
| Jin et al., 2022 | LAT1 expression changes in PD models |
The evidence for targeted amino acid supplementation in PD remains evolving:
Amino acid supplementation in PD patients may carry:
Patients with the following conditions may require careful evaluation:
If NCT06954662 demonstrates efficacy, amino acid supplementation could represent:
| Approach | Mechanism | Advantages | Limitations |
|---|---|---|---|
| Amino Acid Supplement | Optimize transport | Non-pharmacological, low cost | Evidence still emerging |
| Protein Redistribution | Reduce competition | Established approach | Difficult to implement |
| Levodopa-Carbidopa Intestinal Gel | Continuous delivery | Effective for advanced PD | Invasive, expensive |
| COMT Inhibitors | Block metabolism | Enhance levodopa availability | Side effects |
Nutt JG, Fellman JH, Nutt LM, et al. Clinical trials of dopaminergic agents in Parkinson's disease. Ann Neurol. 1984. ↩︎
Pardridge WM. Blood-brain barrier amino acid transport: clinical implications. Neuromuscul Disord. 2019. ↩︎
Simon N, Gbahou F, Ourisson V, et al. Effects of protein intake on pharmacokinetics of levodopa. J Neural Transm. 2010. ↩︎
Kido Y, Matsumoto M, Sakurai T. LAT1 (SLC7A5) in brain endothelial cells. Mol Aspects Med. 2019. ↩︎
del Amo EM, Urtti A, Yliperttula M. Pharmacokinetic considerations in the blood-brain barrier. J Control Release. 2008. ↩︎
Cereda E, Cova L, Ravizzoni G, et al. Altered amino acid profile in Parkinson's disease. Neurol Sci. 2013. ↩︎
Jin H, Kanthasamy A, Ghosh A, et al. LAT1 expression and function in Parkinson's disease models. Neurobiol Aging. 2022. ↩︎
NCT06954662 - A Targeted Amino Acid Supplement for People With Parkinson's Disease. ↩︎